Psychotic Disorders Treatment Development Program
This program supports studies of novel psychopharmacological and somatic approaches to alleviating the full spectrum of symptom domains found in patients with schizophrenia and schizophrenia spectrum disorders, including positive symptoms, deficit symptoms, disorganization, and cognitive deficits associated with these conditions. The program also supports studies that integrate investigations of the mechanisms of treatment response with efficacy of treatments, and studies designed to develop biomarkers and other predictors of treatment response for these conditions.
Areas of Emphasis
- Early-phase clinical studies of new medications targeting major mental illnesses or symptom domains now lacking adequate treatments.
- Studies integrating evaluation of mechanisms of therapeutic response to pharmacological agents with assessment of efficacy.
- Studies to predict treatment response and facilitate individualized pharmacological therapeutics.
- Clinical treatment studies integrating biomarkers with traditional clinical endpoints to validate the clinical utility of putative surrogate markers of treatment response.
- Studies to identify predictors of adverse effects of psychopharmacological agents and intervention development to mitigate these adverse effects.
- Studies of efficacy of novel somatic treatments or medical devices for the treatment of mental illness.
Mi Hillefors, M.D., Ph.D.
6001 Executive Boulevard, Room 7125; MSC 9632